Priya Rastogi MD

Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Medicine, University of Pittsburgh School of Medicine

200 Meyran AveSte 318Pittsburgh, PA 15213
Phone+1 412-383-1650
Fax+1 412-641-1085

Dr. Rastogi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rastogi's full profile Already have an account?

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
Saint Joseph HospitalResidency, Internal Medicine, 1997 - 2000
Wright State University Boonshoft School of MedicineClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification MyUPMC, UPMC, 2013-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
CMS Meaningful Use Stage 1 Certification dbMotion, dbMotion Inc., 2013-2017

Clinical Trials

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
COMPLETED
PHASE3

Publications & Presentations

PubMed

Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.
Eleftherios P Mamounas, Ming Chen, Joseph A Sparano, Md Ashequr Rahman, Yating Cheng
Cancer Research Communications. 2026-07-01
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-define...
Anwaar Saeed, Greg Yothers, Shannon L Puhalla, Alireza Tojjari, Priya Rastogi
Future Oncology. 2026-07-01
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
Ilana Schlam, Gong Tang, Khalid AbdulJabbar, Haixi Yan, Xuelin Gu
NPJ Breast Cancer. 2026-05-14

Lectures

Selected Updates in Breast Cancer
2007 Annual Meeting, Chicago, Illinois, USA
Selected Updates in Breast Cancer
American Society of Clinical Oncology, 2007 Annual Meeting, Chicago, Illinois, USA

Press Mentions

Priya Rastogi on Use of the MammaPrint Assay for Predicting Benefit from Extended LetrozoleJanuary 7th, 2025
Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer SubsetsAugust 30th, 2024
Advantage of Abemaciclib plus Endocrine Therapy for Early Breast Cancer Endures at 5 YearsJanuary 23rd, 2024